Navigation Links
Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
Date:10/19/2011

THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company's Global Commercial Operations.

Hooper, 56, joins Amgen after sixteen years at Bristol-Myers Squibb Company (BMS) where he was most recently senior vice president, Commercial Operations and president, United States, Japan and Intercontinental.  Hooper's broad commercial operations experience includes running the BMS commercial business in North America, Asia, Middle East, Africa, South America and Europe.  

"As we continue to grow, Tony's track record of delivering results and his passion for serving patients across the globe make him an outstanding addition to Amgen's leadership team," Bradway said.

"It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses," said Hooper. "I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion."

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... of their RedySmart™ mass flow meters and controllers ideal for BioPharm ... an ideal upgrade to antiquated rotameters. These thermal instruments employ high-precision MEMS (Micro-Electro ...
(Date:1/22/2020)... ... January 20, 2020 , ... ... with WAVE Electronics, the largest independent electronics distributor in the US, to make ... Smart Home Systems with leading smart home products from a single fulfillment partner. ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and Cardea ... The partners have agreed to co-develop and market a portfolio of CRISPR QC ... programs. Over the longer-term, the parties aim to develop a COBO branded QC ...
(Date:1/10/2020)... ... 09, 2020 , ... A new report from Tufts ... qualification process, a critical element of clinical trial set up and execution. According ... qualification process creates delays in initiation in 7% of clinical trials for biopharma ...
Breaking Biology Technology:
(Date:2/13/2020)... ... February 13, 2020 , ... Pharmica ... to clinical operations executives and focusing on all facets of clinical trial planning ... management, patient engagement, and more. , “We have attended the SCOPE Summit ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... The LaunchPort™ medical device accelerator in Port Covington, Baltimore. The newly formed company ... must be addressed to manage increased demand for home dialysis treatments. The start-up ...
(Date:2/6/2020)... ... 2020 , ... Kerafast Inc. , developers of an ... an agreement with The Good Food Institute , a nonprofit organization committed ... terrestrial meat and aquatic cell lines will be made available to scientists worldwide ...
Breaking Biology News(10 mins):